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Summary
 
Immunoglobulin-like transcript (ILT) 3 is a novel cell surface molecule of the immunoglobulin
superfamily, which is selectively expressed by myeloid antigen presenting cells (APCs) such as
monocytes, macrophages, and dendritic cells. The cytoplasmic region of ILT3 contains puta-
tive immunoreceptor tyrosine-based inhibitory motifs that suggest an inhibitory function of
ILT3. Indeed, co-ligation of ILT3 to stimulatory receptors expressed by APCs results in a dra-
matic blunting of the increased [Ca
 
2
 
1
 
]
 
i
 
 and tyrosine phosphorylation triggered by these recep-
tors. Signal extinction involves SH2-containing protein tyrosine phosphatase 1, which is re-
cruited by ILT3 upon cross-linking. ILT3 can also function in antigen capture and presentation.
It is efficiently internalized upon cross-linking, and delivers its ligand to an intracellular com-
partment where it is processed and presented to T cells. Thus, ILT3 is a novel inhibitory receptor
that can negatively regulate activation of APCs and can be used by APCs for antigen uptake.
 
E
 
ngagement of B cell antigen receptor, TCR, and sev-
eral Fc receptor (FcR) complexes by cognate ligands
results in tyrosine phosphorylation of cytoplasmic immuno-
receptor tyrosine-based activation motifs (ITAMs)
 
1
 
 (1–6).
Phosphorylated ITAMs recruit and activate protein ty-
rosine kinases, which trigger a cascade of intracellular phos-
phorylation events leading to cellular activation. Immune cell
responses are negatively regulated when stimulatory recep-
tors are co-ligated to inhibitory receptors. These include
the low affinity FcR for IgG, Fc
 
g
 
RIIB, and CD22 in B
cells (7–10), the Ly-49 molecules, the killer cell inhibitory
receptors (KIRs), the NKG2A/CD94 heterodimer in NK
cells (11–13), and glycoprotein (gp)49B1 in mast cells and
NK cells (14–16). All of these receptors are characterized by
the presence of cytoplasmic immunoreceptor tyrosine-based
inhibitory motifs (ITIMs; 17). Upon receptor engagement,
cytoplasmic ITIMs are tyrosine phosphorylated, and subse-
quently bind the SH2 domain(s) of SHP-1 protein tyrosine
phosphatase (18–23) and/or SHIP inositol phosphatase
(24), which mediate downregulation of cell activation.
Recently, we have described two new members of the
immunoglobulin superfamily (Ig-SF), called immunoglob-
ulin-like transcript 1 (ILT1) and ILT2 (25). These are ho-
mologous to bovine Fc
 
g
 
2 receptor (Fc
 
g
 
2R; 26), murine cell
surface antigen gp49 (27, 14), human KIRs (28–30), human
Fc
 
a
 
 receptor (Fc
 
a
 
R; 31) and map to human chromosome
19, as do the Fc
 
a
 
R and the KIRs. ILT1 and ILT2 are char-
acterized by similar extracellular regions consisting of four
Ig-SF domains. Their transmembrane and cytoplasmic do-
mains, however, differ substantially. ILT1 has a charged resi-
due of arginine within the transmembrane region, followed
by a short cytoplasmic tail with no ITAMs or ITIMs. Simi-
lar characteristics are found in human Fc
 
a
 
RI and bovine
Fc
 
g
 
2R, which trigger cell responses via associated signal-
transducing, ITAM-containing subunits. Conversely, ILT2
has a long cytoplasmic tail, which contains putative ITIMs
similar to those known to bind SHP-1 in KIRs. ILT1 and
ILT2 also display different tissue distributions. Although
ILT1 is predominantly expressed by myeloid cells, ILT2 is
expressed by B cell lines. Thus, ILT1 and ILT2 may mediate
activation of myeloid cell responses and inhibition of B cell
activation, respectively.
Here we characterize a third member of the ILT family,
called ILT3, which, similarly to ILT2, displays a long cyto-
plasmic tail containing putative ITIMs. By using an anti-
ILT3 mAb, we have found that ILT3 is selectively ex-
 
1
 
Abbreviations used in this paper:
 
 BCR, B cell antigen receptor; DC, dendritic
cells; gp, glycoprotein; HRP, horseradish peroxidase; Ig-SF, Ig superfamily;
ILT, Ig-like transcript; ILT3-HuIgG
 
1
 
, ILT3 human IgG
 
1
 
 fusion protein;
ITAM, immunoreceptor tyrosine-based activation motif; ITIM, immunore-
ceptor tyrosine-based inhibitory motif; KIR, killer cell inhibitory recep-
tor; M-CSF, macrophage CSF; MFI, median fluorescence intensity.
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pressed on myeloid APCs. Functional studies show that
ILT3 behaves as an inhibitory receptor when cross-linked
to a stimulatory receptor. A cytoplasmic component of the
ILT3-mediated negative signaling pathway is the SH2-
containing phosphatase SHP-1, which becomes associated
with ILT3 upon cross-linking. Furthermore, ILT3 is inter-
nalized and ILT3 ligands are efficiently presented to specific
T cells, suggesting that ILT3 may be involved in antigen
uptake and presentation.
 
Materials and Methods
 
Cells.
 
THP1 is a human myeloid cell line. C1R and 721.221
are MHC class I–deficient, EBV-transformed human B cell lines.
Jurkat is a human T cell line. All of these cells were grown in
RPMI, 10% FCS. Monocytes were prepared from PBMCs by
adhesion to plastic. In brief, PBMCs were isolated from whole
blood by Ficoll-Hypaque density gradient, washed with RPMI,
resuspended at 5 
 
3
 
 10
 
6
 
/ml in RPMI, 10% FCS and cultured in
six-well plates for 1 h at 37
 
8
 
C. Nonadherent cells were removed
by washing twice with RPMI. Adherent cells were cultured
overnight in RPMI, 10% FCS supplemented with 50 ng/ml
GM-CSF and 1,000 U/ml IL-4. Dendritic cells (DCs) were ob-
tained from monocytes as previously described (32). Macrophages
were obtained by culturing monocytes for 10 d in six-well plates
at a concentration of 10
 
6
 
 cells/ml in RPMI, 20% human serum
supplemented with 1 ng/ml macrophage CSF (M-CSF) (33, 34).
 
cDNA Synthesis, Oligonucleotide Primers, PCR, and Cloning.
 
The 3
 
9
 
 end of ILT3 was cloned by rapid amplification of cDNA
3
 
9
 
 end (35). In brief, RNA was prepared from 721.221 and C1R
cells as described (36) and single-strand cDNA was synthesized by
reverse transcription of 1 
 
m
 
g of total RNA using Moloney mu-
rine leukemia virus reverse transcriptase and a (dT)
 
17
 
 adaptor in a
reaction volume of 20 
 
m
 
l. cDNA was amplified by two nested
PCRs. The 5
 
9
 
 oligonucleotides were CCCCCAGCGACC-
CCCTGGA (nucleotide 926–944 of ILT2) and ACGGTGGC-
CTCAGGAGAGA (nucleotide 1003–1021 of ILT2) (25). In
both PCRs, the 3
 
9
 
 primer corresponded to the adaptor primer.
PCRs (50 
 
m
 
l volume) contained 1 
 
m
 
l of total cDNA sample,
PCR primers (0.5 
 
m
 
M each), 2
 
9
 
-deoxynucleoside 5
 
9
 
-triphosphates
(125 
 
m
 
M each), 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM
MgCl
 
2
 
, 0.01% gelatin, and 0.25 units of Taq polymerase. PCR
was carried out for 35 cycles, each consisting of 1-min steps at 94,
55, and 72
 
8
 
C. Amplified products were gel purified in 1.2% aga-
rose gel, cloned into pCRII (Invitrogen, San Diego, CA), and se-
quenced. The 5
 
9
 
 end of ILT3 was cloned by two consecutive cy-
cles of 5
 
9
 
 rapid amplification of cDNA ends (35).
 
Production of ILT3 Human IgG
 
1
 
 Fusion Protein.
 
To produce ILT3
as a soluble fusion protein, we constructed a chimeric gene con-
sisting of ILT3 extracellular domains and human IgG1 constant
regions. The cDNA fragment encoding the ILT3 extracellular re-
gion was amplified by PCR from cloned plasmid DNA. The 5
 
9
 
primer (GATC
 
GAATTC
 
ATGATCCCCACCTTCACGGCT)
contained an EcoRI restriction site (
 
italic
 
) and the ILT3 start
codon. The 3
 
9
 
 primer (CTGATC
 
AAGCTT
 
ATACTTACCCT-
CCCAGTGCCTTCTCAGACC) provided a HindIII restriction
site (
 
italic
 
), a splice donor sequence, and seven ILT3 codons pre-
ceding the transmembrane domain. The 
 
z
 
800-bp PCR product
was cut with EcoRI and HindIII, and ligated into an expression
vector containing the exons for hinge, CH2 and CH3 region of
human IgG
 
1
 
, the guanosine phosphotransferase gene conferring
resistance to mycophenolic acid, and the 
 
k
 
 promoter for the ex-
pression in mouse myeloma (37). Transfections, selection of se-
creting transfectants, and purification of fusion protein from cul-
ture supernatants were performed as described (38).
 
Production of anti-ILT3 mAbs.
 
10-wk-old, female BALB/c mice
(Iffa-Credo, L’Arbresle, France) received an initial injection of
100 
 
m
 
g of ILT3 human IgG
 
1
 
 fusion protein (ILT3-HuIgG
 
1
 
),
mixed 1:1 (vol/vol) with Alu-Gel-S (Serva Biochemicals, Para-
mus, NJ), behind the neck. 4 wk later, they were given a booster
immunization with the same immunogen, followed after 2 wk by
a final injection of 100 
 
m
 
g of purified ILT3-HuIgG
 
1
 
. 3 d later,
mice were killed and draining lymph node cells were isolated and
fused with the myeloma fusion partner, Ag8.653, using polyeth-
ylene glycol 4000. Hybridoma supernatants were screened in two
steps. First, an ELISA was performed using ILT3-HuIgG
 
1
 
 in the
coating step and human-adsorbed alkaline phosphatase–labeled
goat anti–mouse IgG as secondary antibody. Supernatants from
clones that were positive in ELISA were then tested by FACS
 
Ò
 
analysis for staining C1R cells by flow cytometry.
 
Transfections.
 
ILT1, ILT2, and ILT3 cDNAs were subcloned
into pCDNA3 (Invitrogen) and transfected into COS7 cells by li-
pofectin (GIBCO BRL, Gaithersburg, MD). Cell surface expres-
sion of ILTs was assessed 48 h after transfection by FACS
 
Ò
 
 analy-
sis. A stable transfectant of ILT3 in Jurkat T cells was obtained as
previously described (28).
 
Antibodies and FACS
 
Ò
 
 Staining.
 
Before staining, all the cells
were preincubated with PBS, 20% human serum for 30 min on
ice, to block Fc receptors. In two- and three-color staining experi-
ments, cells were stained with the following primary mAbs: OKT3
(anti-CD3, IgG2a; American Type Culture Collection, Rockville,
MD), CD16 (IgG2a; Milan Analytica AG, La Roche, Switzerland),
3C10 (anti-CD14, IgG2b; American Type Culture Collection),
1F5.4 (anti-CD20, IgG2a; American Type Culture Collection),
M-T102 (anti-CD1a, IgG2b; PharMingen, San Diego, CA), L243
(anti-HLA-DR, IgG2a; American Type Culture Collection), and
HB15a (anti-CD83, IgG2b; provided by Dr. T. Tedder, Duke
University, Durham, NC). As secondary antibodies, we used hu-
man-adsorbed FITC- or PE-conjugated goat anti–mouse IgG1,
IgG2a, and IgG2b (Southern Biotechnology Assoc., Inc., Birming-
ham, AL). In three-color stainings, biotin-labeled goat anti–mouse
IgG2a was followed by streptavidin-allophycocyanin (SBA). Stained
cells were analyzed by flow cytometry on a FACStar
 
Ò
 
 Plus (Bec-
ton Dickinson, Mountain View, CA) using the LYSYS II software.
 
Immunoprecipitations.
 
Cells were surface labeled with 1 mCi of
Na
 
125
 
I using the sulfosuccinimidyl-3-(4-hydroxyphenyl)propi-
onate method (39). For metabolic labeling with [
 
32
 
P]orthophos-
phate, cells were incubated in phosphate-free DMEM (Sigma
Chemical Co., St. Louis, MO) containing 10% Tris-buffered sa-
line–dialyzed FCS for 1 h. [
 
32
 
P]orthophosphate (Amersham Corp.,
Arlington Heights, IL) was then added at 0.5 mCi/ml and incu-
bation was continued for 5 h. After surface or metabolic labeling,
cells were lysed in 1% Triton X-100, 100 mM Tris-HCl, pH 7.4,
150 mM NaCl, 5 mM EDTA, 1 mM PMSF, 10 
 
m
 
g/ml aproti-
nin, and 10 
 
m
 
g/ml leupeptin. After overnight preclearing with
protein G–sepharose, lysates were incubated with culture super-
natants of either ZM3.8 (anti-ILT3, IgG
 
1
 
) or control IgG1 mAbs
(5.133, anti-NKAT4 [40] and 1B7.11, anti-2,4,6 TNP, American
Type Culture Collection) at 
 
1
 
4
 
8
 
C for 4 h, and immune com-
plexes were precipitated by addition of protein G–Sepharose for 1 h
at 
 
1
 
4
 
8
 
C. Precipitates were washed 3 times with lysis buffer, fol-
lowed by a final wash with 10 mM Tris-HCl, pH 7.4, and resus-
pended in nonreducing or reducing sample buffer. SDS-PAGE
analysis was performed according to a standard procedure. After 
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the run, gels were dried and exposed to autoradiography film
(Amersham Corp.) for 2–5 d.
 
Measurement of Cytosolic Calcium in Macrophages and Mono-
cytes.
 
Monocytes and macrophages were loaded with Indo-1
AM (Sigma Chemical Co.) as described (41). In stimulation ex-
periments, anti-CD11b mAb (44aabc; American Type Culture
Collection) and anti-CD16 mAb (B73.1; American Type Culture
Collection) were added to monocytes and macrophages, respec-
tively, followed by a F(ab
 
9
 
)
 
2
 
 goat anti–mouse IgG (Milan Analytica)
as cross-linker. Cells were then analyzed on a flow cytofluorime-
ter (FACS
 
Ò
 
 Vantage or Coulter Elite Enhanced Sort Performance
[Coulter Corp., Hialeah, FL]) to detect Ca
 
2
 
1
 
 fluxes. Stimulation
of monocytes with the anti-HLA-DR mAb 3.8B1 (Cella, M.,
and A. Lanzavecchia unpublished data) was performed without a
cross-linker. In inhibition experiments, cells were preincubated
for 10 min at room temperature either with ZM3.8 mAb, or with
the anti–MHC class I W6/32 mAb. After washing with PBS, ei-
ther anti-CD11b, anti-HLA-DR, or anti-CD16 mAbs were added
followed by the cross-linking antibody, and cells were analyzed
by flow cytometry to detect Ca
 
2
 
1
 
 fluxes. Only live (based on for-
ward scatter criteria) and Indo-1–loaded cells (based on 405 nM
versus 525 nM emission spectra) were included in the analysis.
 
Immunoblotting.
 
For antiphosphotyrosine blots, monocytes (2 
 
3
 
10
 
6
 
) were incubated for 2 min at 37
 
8
 
C with medium, ZM3.8
mAb, 3.8B1 mAb, or with both mAbs in the absence or in the
presence of a secondary cross-linker. Cells were washed in ice-
cold PBS and lysed as previously described (20). Cell lysates were
boiled, separated on SDS-PAGE, transferred to nitrocellulose,
and probed with horseradish peroxidase (HRP)-coupled 4G10
(500 ng/ml; Upstate Biotechnology Inc., Lake Placid, NY). Im-
munoblotted proteins were visualized by chemiluminescence us-
ing the enhanced chemiluminescence detection reagents (Amer-
sham Corp.). For anti-SHP blots, 10
 
7
 
 monocytes were plated on
six-well tissue culture plates previously coated with purified
ZM3.8 or 5.133 mAbs at 50 
 
m
 
g/ml, centrifuged for 2 min,
shifted to 37
 
8
 
C for 2 min, collected in cold PBS, 0.5 mM EDTA,
and washed twice. Identical number of cells stimulated with
ZM3.8 or 5.133 mAbs were lysed and immunoprecipitated with
ZM3.8 and protein G as described above. Precipitated samples
were boiled for 5 min, separated by SDS-PAGE, and transferred
to nitrocellulose (Hybond-C extra; Amersham Corp.). Mem-
branes were blocked with PBS, 3% nonfat, dry milk and probed
anti-SHP-1 rabbit antiserum (Santa Cruz Biotechnology, Santa
Cruz, CA) followed by HRP-labeled goat anti–rabbit Ig (SBA).
Immunoblotted proteins were visualized by chemiluminescence.
Membranes were stripped of antibody by incubating for 30 min
at 50
 
8
 
C in 100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-
HCL, pH 6.7, according to the protocol supplied by Amersham
Corp. Stripped blots were reprobed after blocking with anti-
SHP-2 rabbit antiserum (Santa Cruz Biotechnology).
 
Internalization Assay.
 
Monocytes were cultured for 24–48 h
in culture medium containing GM-CSF and IL-4, as described
above. One aliquot of monocytes was fixed for 1 min at room
temperature in RPMI, 0.05% glutaraldehyde. Another aliquot
was used without fixation. Both samples were stained with
ZM3.8 mAb for 40 min on ice, washed twice with ice-cold PBS,
1% FCS, and subsequently stained with biotin-labeled F(ab
 
9
 
)
 
2
 
goat anti–mouse IgG for 1 h on ice. After washing with ice-cold
PBS, 1% FCS, cells were incubated at 37
 
8
 
C in prewarmed
RPMI, 10% FCS for various times to allow internalization. Cells
were then cooled on ice, washed once with PBS, 0.1% NaN
 
3
 
,
stained with PE-conjugated streptavidin for 30 min on ice,
washed, and analyzed by FACS
 
Ò
 
. As a measure of internalization
in nonfixed cells, we used the percental decrease of the median
fluorescence intensity (MFI) as compared to control samples kept
at 4
 
8
 
C. The percentage decrease of MFI observed in fixed cells was
taken as a measure of the off-rate of the antibody at 37
 
8
 
C.
 
Antigen Presentation Assay.
 
4 
 
3
 
 10
 
4
 
 irradiated monocytes (3,000
rad) were co-cultured with 8 
 
3
 
 10
 
4
 
 cells of the B13 T cell clone
(42) in 96-well flat-bottom microplates in the presence of serial
dilutions of IgG1 mAbs. mAbs used in the assay were the follow-
ing: ZM3.8 (anti-ILT3, IgG
 
1
 
) or 5.133 (anti-NKAT4 KIR,
IgG
 
1
 
), 1B7.11 (anti-2,4,6 TNP, IgG
 
1
 
; American Type Culture
Collection), and 32.2 (anti-Fc
 
g
 
RI, IgG1; American Type Culture
Collection). After 48 h, the cultures were pulsed with [3H]thymi-
dine (1 mCi/well, specific activity 5 Ci/mmol), and the radioac-
tivity incorporated was measured after additional 16 h. The data
were plotted against the concentration of mAbs determined by
ELISA using a purified mouse IgG1 (anti-CD68, Dako Corp.,
Carpinteria, CA) as a standard.
Figure 1. Amino acid se-
quence of human ILT3, aligned
with ILT1 and ILT2. Since ILT1
and ILT2 consist of four Ig-SF
domains, only the two domains
with higher homology to ILT3
were included in the alignment.
The alignment was generated by
the Clustal method. Gaps (dashes)
were introduced to maximize
homologies. Amino acids identi-
cal to the consensus are indicated
by dots. Conserved cysteines in-
volved in disulfide bonds in the
extracellular domains are identi-
fied by asterisks. Cytoplasmic ty-
rosine-based motifs potentially
involved in signal transduction
and/or endocytosis are boxed.
ILT3 has no N-linked glycosylation sites (N-X-S/T). Amino acid residues are numbered on the right side, beginning with the first residue of each of the
predicted domains. ss, signal sequence; Ig1–4, Ig-SF extracellular domains; cp, connecting peptide; tm, transmembrane domain; cy, cytoplasmic domain.
ILT3 cDNA sequence is available from EMBL/GenBank/DDBJ under accession number U82979.1746 An Inhibitory Receptor Expressed in Myeloid Antigen-presenting Cells
Results
ILT3 Is a Member of the ILT Multigene Family Located on
Human Chromosome 19. During the process of cloning the 39
end of ILT2 cDNA from EBV-B cell lines (25), we ob-
tained an additional cDNA sequence that differed from
ILT2 by several amino acid residues. Amplification of the
59 end of this fragment yielded a new cDNA, called ILT3,
which contains a single open reading frame encoding a
transmembrane protein of 447 amino acids with a predicted
molecular mass of z47 kD (Fig. 1). The amino acid se-
quence begins with a hydrophobic signal peptide of 23
amino acids followed by an extracellular region composed
of two C2 type Ig-SF domains (43). Each domain shows
two characteristic cysteines that are 49 and 50 residues
apart, flanked by conserved residues (Val-x-Leu/Ile-x-Cys
and His/Tyr-x-Gly-x-Tyr-x-Cys-Tyr/Phe, respectively,
where x is any amino acid). The putative transmembrane
domain of ILT3 consists of 21 amino acids, followed by a
long cytoplasmic region of 167 amino acids, which is char-
acterized by the presence of one Tyr-x-x-Val motif fol-
lowed by two Tyr-x-x-Leu motifs spaced by 26 amino acid
residues. These Tyr-x-x-Leu pairs and their spacing are
reminiscent of the Tyr-x-x-Leu motifs identified in KIRs
as binding sites for protein tyrosine phosphatase SHP-1
(19–23).
Comparison of the predicted amino acid sequence of
ILT3 with Ig-SF protein sequences, revealed that ILT3 is
closely related to ILTs (64% similarity with ILT2), bovine
Fcg2R (45%), murine cell surface antigen gp49 isoforms
(39–43%), and, to a lesser extent, to KIRs (23–32%) and
human FcaR (28%). Genomic DNA analysis of human–
hamster hybrid cell lines, each with a different partial com-
plement of human chromosomes, showed hybridizing
bands only in samples containing human chromosome 19
(data not shown). Thus, ILT3 belongs to the ILT family
which maps to human chromosome 19, as do the FcaR
and the KIR genes. Expression of ILT3 by RNA blot anal-
ysis revealed a major transcript of z1.6 kb (data not
shown). Interestingly, this transcript was weakly expressed
in the B cell lines C1R or 721.221, from which ILT3 was
initially cloned, whereas it was predominantly expressed in
monocytes purified from PBMCs and in the myeloid cell line
THP1. No transcripts were detected in the T cell line Jurkat.
ILT3 Is Expressed on Monocytes, Macrophages, and Dendritic
Cells. To characterize the ILT3-encoded cell surface mol-
Figure 2. Expression of ILT3 in monocytes, primary DCs, monocyte-derived DCs, and macrophages. (A) mAb ZM3.8 stains CD141 monocytes in
PBMC and CD831 DCs in a monocyte-enriched population (right). On the contrary, CD31 T cells, CD161 NK cells, or CD201 B cells are not stained
(left). PBMCs and monocyte-enriched populations were subjected to two-color staining. Lymphocytes (left) and monocytes (right) were gated using for-
ward and side scatter (FSC and SSC) parameters. (B) ILT3 is expressed on CD141 monocytes and on a subset of CD14-/HLA-DRhigh cells, which cor-
responds to circulating primary DCs (46). Monocytes were enriched from peripheral blood and subjected to three-color staining using anti-CD14
(FITC), ZM3.8 (PE), and anti-HLA-DR (APC). (C) Monocyte-derived DCs express both CD1a and ILT3. (D) Macrophages express low levels of both
CD16 and ILT3. DCs and macrophages were derived from monocytes under appropriate culture conditions and subjected to two-color staining. Nega-
tive controls were located in the lower left quadrants.1747 Cella et al.
ecule, we produced anti-ILT3 mAbs using a soluble ILT3-
HuIgG1 fusion protein as an immunogen. The ZM3.8 mAb
specifically recognized ILT3 on transiently transfected COS
cells (data not shown). In PBMCs, ZM3.8 mAb stained
only CD141 monocytes, whereas no staining was observed in
CD31 T cells, CD161 NK cells, or CD201 B cells (Fig. 2
A). Interestingly, in monocyte-enriched populations de-
rived from peripheral blood, ZM3.8 also stained CD831
cells (Fig. 2 A), as well as CD14-/HLA-DRhigh cells (Fig. 2
B). Both of these cell populations correspond to circulating
primary DCs (44–46). In addition, ILT3 was expressed by
both DCs and macrophages derived from monocytes cul-
tured with GM-CSF plus IL-4 or M-CSF, respectively
(Fig. 2, C and D; 32–34).
We also tested ILT3 expression in several cell lines.
Among four myelo-monocytic cell lines (U937, Monomac6,
THP1, and HL-60), only THP1 reacted with ZM3.8. All
tested EBV-B cell lines (n 5 10) were negative, with the ex-
ception of C1R. No cell surface expression was detected ei-
ther on purified fresh B cells or on B cells activated by CD40L
in the presence of IL-4, IL-2, and IL-10 (data not shown).
Finally, ZM3.8 did not stain neutrophils (data not shown).
Thus, ILT3 is selectively expressed on myeloid APCs.
To define the biochemical characteristics of ILT3, we
carried out immunoprecipitations from ILT3-transfected
Jurkat T cells and monocytes (Fig. 3). A prominent band of
z55 kD in ILT3-transfected T cells was detected under
nonreducing and reducing conditions, while a z58–60 kD
band was detected in monocytes (Fig. 3 A) and in THP1
(data not shown). N- and O-deglycosylation of immuno-
precipitates did not produce any change in the size of the
bands. After labeling cells with [32P]orthophosphate, ILT3
was immunoprecipitated as a constitutively phosphorylated
molecule (Fig. 3 B). The discrepancy in apparent molecular
mass of ILT3 between ILT3-transfected T cells and mono-
cytes may be due to a different degree of phosphorylation
in distinct cell types.
Intracellular Ca21 Mobilization Responses Triggered by
CD11b, MHC Class II, and CD16 in APCs Are Negatively
Regulated by Co-ligation with ILT3. The presence of puta-
tive ITIMs suggested an inhibitory role of ILT3 on APC
activation. To test this hypothesis, we triggered monocytes
and macrophages with mAbs that have been shown to in-
duce Ca21 mobilization, such as anti-CD11b (47, 48), anti-
HLA-DR (49–51), and anti-FcgRIII (CD16; 52) mAbs,
and tested whether recruitment of ILT3 to the triggering
receptors inhibits Ca21 mobilization. As shown in Fig. 4 A,
ligation of surface CD11b with a specific mAb followed by
a secondary cross-linking antibody elicited a rapid and tran-
sient rise in intracellular calcium concentration ([Ca21]i).
On the contrary, preincubation of monocytes with ZM3.8
mAb, followed by addition of anti-CD11b and co-cross-
linking of CD11b and ILT3 by a secondary antibody, re-
sulted in complete inhibition of the [Ca21]i increase (Fig. 4
D). In control experiments, the [Ca21]i increase induced by
CD11b was not affected by co-ligation of CD11b with
MHC class I. Also, cross-linking of ILT3 alone did not evoke
Ca21 mobilization, indicating that ILT3 is not a stimulatory
receptor (data not shown).
It has been reported that some anti–MHC class II mAbs
can trigger functional responses in B lymphocytes (49–51).
We have recently developed an anti-HLA-DR mAb,
called 3.8B1, which triggers a rapid rise in [Ca21]i, even in
the absence of a secondary cross-linking antibody (Fig. 4
B). Co-ligation of ILT3 and HLA-DR resulted in signifi-
cant inhibition of [Ca21]i increase (Fig. 4 E). Interestingly,
HLA-DR–mediated stimulation of monocytes was not af-
fected by preincubation of monocytes with anti-ILT3 anti-
Figure 3. (A) SDS-PAGE analysis of ILT3 immunoprecipitated from
125I-labeled, ILT3-transfected Jurkat T cells and monocytes. ILT3 appears
as a z55-kD band in ILT3-transfected cells and as a z58–60-kD band in
monocytes. (B) When ILT3 is precipitated from 32P-labeled cells, it is de-
tectable as a constitutively phosphorylated molecule.
Figure 4. Intracellular Ca21 mobilization induced in monocytes and
macrophages via CD11b (A), HLA-DR (B), and FcgRIII (C) are inhib-
ited upon cross-linking with ILT3 (D–F). G shows that in the absence of
a cross-linking antibody, ILT3 does not inhibit Ca21 flux triggered by the
3.8B1 anti-HLA-DR mAb.1748 An Inhibitory Receptor Expressed in Myeloid Antigen-presenting Cells
body in the absence of the secondary cross-linking anti-
body, indicating that recruitment of ILT3 to the stimulatory
receptor is necessary to block the [Ca21]i increase (Fig. 4 G).
The low affinity receptor for IgG, FcgRIII, is expressed
on NK cells and macrophages and has been shown to trig-
ger Ca21 mobilization in NK cells (52, 53). Similarly, we
showed that cross-linking of FcgRIII in macrophages evokes
a strong increase of [Ca21]i (Fig. 4 C). Despite the low ex-
pression of ILT3 on macrophages (see Fig. 2 D), co-liga-
tion of ILT3 and FcgRIII inhibited the [Ca21]i increase,
especially at early time points (Fig. 4 F). Together, these
results demonstrate that co-ligation of ILT3 with a trigger-
ing receptor results in signal extinction.
SHP-1 Is Recruited to ILT3 upon Cross-linking. To test
whether inhibition of Ca21 mobilization responses was par-
alleled by inhibition of tyrosine phosphorylation, we per-
formed antiphosphotyrosine immunoblotting on whole cell
lysates of monocytes stimulated via HLA-DR in the absence
or in the presence of co-ligation with ILT3. As shown in
Fig. 5 A, monocytes triggered via HLA-DR displayed a sub-
stantial increase of tyrosine phosphorylation (lane 3), as com-
pared to monocytes incubated with medium alone (lane 1)
or with anti-ILT3 mAb (lane 2). Co-ligation of ILT3 with
HLA-DR resulted in a dramatic reduction of the intensity
and number of tyrosine phosphorylated species (lane 5). In
the absence of secondary cross-linking antibody, ILT3 did
not block HLA-DR–triggered tyrosine phosphorylation
increase (lane 4).
Since in NK cells, KIRs downregulate calcium mobiliza-
tion and tyrosine phosphorylation by recruiting SHP-1 and
SHP-2 (19–23), we tested whether these phosphatases
could be also involved in the negative signaling pathway
mediated by ILT3. ILT3 was cross-linked on monocytes by
ZM3.8 mAb attached to the plastic surface of tissue culture
plates and subsequently immunoprecipitated from cell ly-
sates. In control experiments, ILT3 was immunoprecipi-
tated from unstimulated cells. Immunoblotting of immu-
noprecipitates with anti-SHP-1 antibodies demonstrated
association of SHP-1 with ILT3 that significantly increases
upon ILT3 cross-linking (Fig. 5 B). On the contrary, no as-
sociation with SHP-2 was detected (data not shown).
These results implicate SHP-1 as a cytosolic component of
the signal extinction mediated by ILT3.
Cross-linking of ILT3 on Monocytes Results in Receptor Inter-
nalization and Delivery into an Antigen-processing Compart-
ment. Since ILT3 is selectively expressed on APCs and
displays putative tyrosine-x-x-valine/leucine internaliza-
tion motifs in the cytoplasmic tail (54–56), we analyzed the
ability of ILT3 to endocytose and deliver its ligand to an
antigen-processing and loading compartment. As shown in
Fig. 6, ZM3.8 mAb bound at 08C to monocytes was not
internalized when the cells were shifted to 378C. We
therefore examined whether internalization occurs in the
presence of a secondary cross-linker. ZM3.8 mAb was
bound on ice to monocytes and cross-linked by a biotiny-
lated F(ab9)2 secondary antibody. Cells were subsequently
warmed to 378C to allow internalization. After various
time points, cells were returned to ice and the amount of
ZM3.8 mAb remaining on the cell surface was determined
by flow cytometry using PE-conjugated streptavidin. Freshly
isolated monocytes efficiently internalized bound ZM3.8
mAb, as demonstrated by a 60–80% reduction after 30 min
at 378C and by a complete disappearance after 60–90 min
(Fig. 6). In control experiments, no significant decrease of
surface-bound ZM3.8 was observed using fixed mono-
cytes, ruling out a detachment of the primary or secondary
antibodies from the cell surface at 378C (Fig. 6). In addi-
Figure 5. (A) Protein tyrosine
phosphorylation stimulated by
treatment of monocytes with the
anti-HLA-DR mAb 3.8B1 is in-
hibited by co-ligation of HLA-
DR with ILT3. Monocytes were
incubated with medium alone
(lane  1), with ZM3.8 mAb (anti-
ILT3; lane 2), with 3.8B1 mAb
(anti-HLA-DR; lane 3) or with
both mAbs in the absence (lane
4) or in the presence (lane 5) of a
secondary cross-linking anti-
body. Cell lysates were sepa-
rated on SDS-PAGE, trans-
ferred to nitrocellulose, and
probed with HRP-coupled an-
tiphosphotyrosine mAb 4G10.
(B) Association of SHP-1 with
ILT3 is increased upon ILT3
cross-linking. Monocytes were
stimulated with ZM3.8 (lane 2)
or with a control IgG (5.133
mAb) (lane 1) coated on plastic
plates. Cells were kept at 378C for 2 min, harvested, and lysed. ILT3 was
immunoprecipitated with ZM3.8. Proteins were separated on SDS-
PAGE, transferred to nitrocellulose, and probed with anti-SHP-1, fol-
lowed by HRP-conjugated goat anti–rabbit Ig. The migration of SHP-1
is marked by the arrow.
Figure 6. ZM3.8 mAb is in-
ternalized upon cross-linking.
ZM3.8 bound to monocytes on
ice did not disappear from the
cell surface when the cells were
shifted at 378C, in the absence of
a cross-linking antibody (m). Af-
ter cross-linking with a F(ab9)2
biotin-labeled secondary anti-
body, ZM3.8 was rapidly inter-
nalized, becoming undetectable
by FACSÒ analysis in 30–60 min
(h). In fixed cells, only a mini-
mal decrease of the median fluo-
rescence intensity was detected
over time (j). Cell surface–
bound ZM3.8 was revealed by
PE-conjugated goat anti–mouse
IgG1 (m) or by PE-conjugated
streptavidin (h, j). The MFI
was determined by FACSÒ anal-
ysis. The percentage decrease of
MFI as compared to a control
sample kept at 48C was used as a
measure of internalization.1749 Cella et al.
tion, when 125I-labeled streptavidin was added as a third
step reagent before incubation at 378C, no significant de-
crease of cell-bound radioactivity was observed over time,
thus excluding shedding of ILT3 from the cell surface (data
not shown).
To further investigate a possible role of ILT3 in antigen
capture, we evaluated the ability of monocytes to present
ZM3.8 mAb to a CD41 class II–restricted T cell clone spe-
cific for a mouse IgG1 peptide epitope (42). The presenta-
tion of the ZM3.8 mAb was compared to that of IgG1
mAbs that bind to other receptors (anti-FcgRI mAb) or do
not bind to surface molecules and are taken up in the fluid
phase [anti-TNP and anti-NKAT4 KIR mAbs]. As shown
in Fig. 7, monocytes presented ZM3.8 mAb to T cells 50–
100-fold more efficiently than the anti-FcgRI mAb, and
400–500-fold more efficiently than anti-TNP and anti-
NKAT4 KIR mAbs. Together, these experiments indicate
that ILT3 can efficiently deliver its ligand to an intracellular
compartment where class II loading can occur.
Discussion
Previous work has extensively shown that inhibitory re-
ceptors regulate cell activation in B, NK, mast cells, and
subsets of T cells when co-ligated with ITAM-containing
stimulatory receptor complexes. Our data extend this con-
cept to professional APCs, showing that ILT3 negatively
regulates APC functional responses triggered via stimula-
tory receptors, such as CD11b, CD16, and even MHC
class II. In addition to its inhibitory function, ILT3 is in-
volved in antigen uptake. It is noteworthy that ILT3 is ex-
pressed on DCs. These are a unique type of leukocytes
whose primary function is to efficiently capture antigens,
process them, and present them to naive T cells (57). Al-
though the uptake and processing of antigen is a major
function of DCs, only a few mechanisms and receptors spe-
cialized for antigen capture have been identified on DCs
(58–60). Our data indicate that ILT3 is a unique receptor
expressed in DCs, able to target the ligand into processing
and peptide-loading compartments. Thus, ILT3 displays a
dual function of inhibitory receptor and antigen-capturing
molecule. A similar dual function has been previously shown
for the low affinity receptor for IgG, FcgRIIB (7, 8).
The ligand of ILT3 is still unknown. ILT3 is closely re-
lated to bovine Fcg2R and, to a lesser extent, to human
FcaR, suggesting that ILT3 may be an Fc receptor. How-
ever, we did not detect any significant binding of human
monomeric and heat-aggregated IgM, IgG, IgA, and IgE to
ILT3-transfected Jurkat T cells (data not shown). ILT3 also
shows homology to KIRs, which suggests that it may be a
receptor for MHC class I molecules. We have investigated
this possibility by analyzing binding of soluble ILT3-
HuIgG1 fusion protein to MHC class I transfectants in the
class I–deficient mutant 721.221. No significant binding
could be detected by FACSÒ analysis under the same ex-
perimental conditions in which KIR-HuIgG fusion pro-
teins bind to MHC class I molecules (data not shown). We
are investigating the possibility that ILT3 is a receptor for
cell surface molecules related to MHC class I molecules,
such as nonclassical class I molecules (CD1 [61], MR1 [62],
MIC [63]), for MHC class II molecules, or for serum fac-
tors such as complement components.
ILT3 is a member of the ILT subfamily of Ig-SF mole-
cules, which is located on chromosome 19, most likely in
close linkage with KIRs. Another member of this family,
ILT2, is characterized by similar cytoplasmic tyrosine-based
motifs such as ILT3, and is expressed in B cell lines, sug-
gesting that this may be a putative inhibitory resceptor in B
cells. We have also cloned additional cDNAs which en-
code novel molecules homologous to ILT2 and ILT3
(ILT4 and ILT5, GenBank accession numbers AF000574
and AF000575). Thus, the number of Ig-SF inhibitory re-
ceptors with different tissue distribution and specificity is
likely to increase.
Figure 7. Presentation of ZM3.8 mAb to a T cell clone specific for
mouse IgG1 by irradiated monocytes. ZM3.8 mAb (j) is presented 50–
100-fold more efficiently than anti-FcgRI (h) and 400–500-fold more
efficiently than anti-TNP (d) and anti-NKAT4 KIR (s) mAbs, which
do not stain monocytes.
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